52 results on '"bruton’s tyrosine kinase"'
Search Results
2. Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments
3. Bruton’s tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder
4. Tyrosine Kinases: Targets for Epigenetic Influences and a New Direction in the Treatment of Multiple Sclerosis
5. BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner
6. [18F]BTK-1: A Novel Positron Emission Tomography Tracer for Imaging Bruton’s Tyrosine Kinase
7. Agammaglobulinemia: from X-linked to Autosomal Forms of Disease
8. Rare deleterious mutations in Bruton’s tyrosine kinase as biomarkers for ibrutinib-based therapy: an in silico insight
9. Design, Synthesis of New Pyrazolo[3,4-d]Pyrimidine Derivatives and In Vitro Evaluation of Antiproliferative Activity against Leukemia Cell Lines
10. Targeting Bruton’s tyrosine kinase in vitreoretinal lymphoma: an open-label, prospective, single-center, phase 2 study
11. Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma
12. Bruton’s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment
13. The Use of Bruton’s Tyrosine Kinase Inhibitors to Treat Allergic Disorders
14. Enhanced Bruton’s tyrosine kinase activity in the kidney of patients with IgA nephropathy
15. Aberrantly expressed Bruton’s tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells
16. BTK targeting suppresses inflammatory genes and ameliorates insulin resistance
17. Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease
18. Targeted selective degradation of Bruton’s tyrosine kinase by PROTACs
19. Observations on the use of Bruton’s tyrosine kinase inhibitors in SAR-CoV-2 and cancer
20. Bruton’s tyrosine kinase drives neuroinflammation and anxiogenic behavior in mouse models of stress
21. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton’s tyrosine kinase inhibitors
22. Inhibition of Bruton’s Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer’s Disease
23. Extracellular vesicles and their associated miRNAs as potential prognostic biomarkers in chronic lymphocytic leukemia
24. Development of piperidinyl dipyrrrolopyridine-based dual inhibitors of Janus kinase and Bruton’s tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis
25. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
26. Water molecules in protein–ligand interfaces. Evaluation of software tools and SAR comparison
27. Delayed diagnosis of X-linked agammaglobulinaemia in a boy with recurrent meningitis
28. Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia
29. Enhanced Bruton’s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis
30. Pharmacophore modeling and virtual screening in search of novel Bruton’s tyrosine kinase inhibitors
31. Damaging BTK Variant Demonstrated by Carrier, Allele-Specific BTK Expression in B Cells and Monocytes
32. Increased expression of Bruton’s tyrosine kinase in peripheral blood is associated with lupus nephritis
33. Role of Bruton’s tyrosine kinase in B cells and malignancies
34. Expression of Bruton’s tyrosine kinase in B-cell neoplasms evaluated by flow cytometry
35. Ibrutinib: from bench side to clinical implications
36. Mutations in Bruton’s tyrosine kinase impair IgA responses
37. Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib
38. X-Linked Agammaglobulinemia Associated with B-Precursor Acute Lymphoblastic Leukemia
39. Ibrutinib in B-cell Lymphomas
40. Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors
41. B-lymphocyte tolerance and effector function in immunity and autoimmunity
42. Increased Pro-inflammatory Cytokine Production After Lipopolysaccharide Stimulation in Patients with X-linked Agammaglobulinemia
43. Mutation of the BTK Gene and Clinical Feature of X-Linked Agammaglobulinemia in Mainland China
44. X-linked hypogammaglobulinemia and isolated growth hormone deficiency: an update
45. X-linked hypogammaglobulinemia and isolated growth hormone deficiency: an update
46. X-Linked Agammaglobulinemia Diagnosed in Adulthood: A Case Report
47. Identification of mutations in the Bruton's tyrosine kinase gene, including a novel genomic rearrangements resulting in large deletion, in Korean X-linked agammaglobulinemia patients
48. PKCβ modulates antigen receptor signaling via regulation of Btk membrane localization
49. The transcription factor, Bright, and immunoglobulin heavy chain expression
50. Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.